These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26982646)

  • 21. [The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
    Karel I
    Cesk Slov Oftalmol; 2007 Sep; 63(5):311-9. PubMed ID: 17915581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries.
    Lad EM; Hammill BG; Qualls LG; Wang F; Cousins SW; Curtis LH
    Am J Ophthalmol; 2014 Sep; 158(3):537-43.e2. PubMed ID: 24857687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age-related macular degeneration: diagnosis and management.
    Cook HL; Patel PJ; Tufail A
    Br Med Bull; 2008; 85():127-49. PubMed ID: 18334518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N; Damico L; Shams N; Lowman H; Kim R
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of age-related macular degeneration.
    Mohan KC; Shukla D; Namperumalsamy P; Kim R
    J Indian Med Assoc; 2003 Aug; 101(8):471-4, 476. PubMed ID: 15071799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).
    Rasmussen H; Chu KW; Campochiaro P; Gehlbach PL; Haller JA; Handa JT; Nguyen QD; Sung JU
    Hum Gene Ther; 2001 Nov; 12(16):2029-32. PubMed ID: 11727737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A; Stinnett S; Fekrat S
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation studies of ranibizumab for neovascular age-related macular degeneration.
    Bloch SB
    Acta Ophthalmol; 2013 Nov; 91 Thesis7():1-22. PubMed ID: 24206851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New treatments for age-related macular degeneration.
    Mittra RA; Ramsay RC
    Minn Med; 2009 Jun; 92(6):41-4. PubMed ID: 19653472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Correctly evaluate the role of visual acuity in age-related macular degeneration treatment].
    Zhang F
    Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):103-5. PubMed ID: 22490943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.
    Tufail A; Patel PJ; Egan C; Hykin P; da Cruz L; Gregor Z; Dowler J; Majid MA; Bailey C; Mohamed Q; Johnston R; Bunce C; Xing W;
    BMJ; 2010 Jun; 340():c2459. PubMed ID: 20538634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
    Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age-related macular degeneration and blindness due to neovascular maculopathy.
    Ferris FL; Fine SL; Hyman L
    Arch Ophthalmol; 1984 Nov; 102(11):1640-2. PubMed ID: 6208888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-related macular degeneration.
    Murphy RP
    Ophthalmology; 1986 Jul; 93(7):969-71. PubMed ID: 2429244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age-related macular degeneration: what's new.
    Koh AH; Ang CL
    Ann Acad Med Singap; 2002 May; 31(3):399-404. PubMed ID: 12061304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study.
    French DD; Margo CE
    Retina; 2011 Jun; 31(6):1036-42. PubMed ID: 21836410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Age-related macular degeneration (AMD)--therapeutic possibilities and new approaches].
    Körner-Stiefbold U
    Ther Umsch; 2001 Jan; 58(1):28-35. PubMed ID: 11217484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AMD--the retinal disease with an unprecised etiopathogenesis: in search of effective therapeutics.
    Nowak JZ
    Acta Pol Pharm; 2014; 71(6):900-16. PubMed ID: 25745762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial.
    Chang TS; Bressler NM; Fine JT; Dolan CM; Ward J; Klesert TR;
    Arch Ophthalmol; 2007 Nov; 125(11):1460-9. PubMed ID: 17998507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current concepts in pathogenesis of age-related macular degeneration].
    Kubicka-Trząska A; Karska-Basta I; Romanowska-Dixon B
    Klin Oczna; 2014; 116(4):277-82. PubMed ID: 25906640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.